CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Feraheme +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02006108
NCT02006108N/ACompleted
CompareCT.gov

Non-invasive MR Imaging Diagnosis of Transplant Rejection

Stanford University·interventional·Posted Dec 9, 2013·Updated May 11, 2018

In Brief

A clinical study evaluating Feraheme and MRI-GE Healthcare 3 Tesla magnet for Renal Transplant Rejection. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and non-rejected transplants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplant Rejection
CountriesUnited States
CollaboratorsLucile Packard Children's Hospital

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 9, 2013
Enrollment StartNov 27, 2012
Primary CompletionApr 11, 2017
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.6 years ago

Interventions

Ferahemedrug

Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging

MRI-GE Healthcare 3 Tesla magnetother

All patients will undergo